Ayuko Yamamura
Overview
Explore the profile of Ayuko Yamamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakai D, Chung H, Oh D, Park S, Kadowaki S, Kim Y, et al.
Cancer Chemother Pharmacol
. 2017 Oct;
80(6):1197-1207.
PMID: 29071414
Purpose: Mesenchymal-epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics of emibetuzumab, a bivalent monoclonal anti-MET antibody that...
2.
Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T
J Diabetes Investig
. 2014 May;
2(6):448-56.
PMID: 24843529
Unlabelled: Aims/Introduction: We assessed the long-term (52 weeks) safety and efficacy of exenatide b.i.d. in Japanese patients with type 2 diabetes and suboptimal glycemic control. Materials And Methods: Participants completing...
3.
Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, Boardman M, et al.
J Diabetes Investig
. 2014 May;
2(3):210-7.
PMID: 24843486
Unlabelled: Aims/Introduction: To evaluate the efficacy and safety of the glucagon-like peptide-1 receptor agonist, exenatide, in Japanese patients with type 2 diabetes mellitus suboptimally controlled despite therapeutic doses of a...
4.
Iwamoto K, Nasu R, Yamamura A, Kothare P, Mace K, Wolka A, et al.
Endocr J
. 2009 Aug;
56(8):951-62.
PMID: 19706990
This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly (QW) in 30 Japanese patients with type 2 diabetes (T2D) suboptimally controlled by...
5.
Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka A, Brodows R
Endocr J
. 2009 Feb;
56(3):415-24.
PMID: 19194050
This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus...
6.
Kothare P, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo K, et al.
J Clin Pharmacol
. 2008 Dec;
48(12):1389-99.
PMID: 19047364
In this single-blind, parallel, placebo-controlled study, the pharmacokinetics, pharmacodynamics, tolerability, and safety of subcutaneous exenatide were evaluated in 40 Japanese patients with type 2 diabetes. Patients were allocated to 4...
7.
Ishii H, Anderson Jr J, Yamamura A, Takeuchi M, Ikeda I
Diabetes Res Clin Pract
. 2008 May;
81(2):169-78.
PMID: 18495289
Objective: To investigate the impact of insulin lispro on patients' quality of life (QOL) in diabetic patients who need insulin treatment. Methods: In this open-label, 12-week study 770 diabetic patients...